Jim McGorry’s guiding focus after over three decades in the life-sciences industry: “Make a difference in the lives of patients.” McGorry is a career executive in the biotech industry, helming cardiac and oncology operations at Genzyme Corp and serving in executive roles at Champions Oncology and Baxter Healthcare. Based in Boston, Massachusetts, McGorry most recently led biotech startup Biostage as CEO to its first successful application for an investigational new drug with the U.S. Food and Drug Administration. McGorry holds an MBA in general healthcare from the Duke University Fuqua School of Business, and Bachelor of Science & Engineering from the U.S. Military Academy at West Point, where he was president of his class

Roger D. Kamm is the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT. He is the recipient of numerous awards including the ASME Lissner Award and the European Society of Biomechanics Huiskes Medal. Since 2010, he has been the Director of the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems. He was elected to be a member of the National Academy of Medicine in 2010. A primary objective of Kamm’s research group is the application of fundamental concepts in fluid and solid mechanics to better understand essential biological and physiological phenomena. His lab focuses on the molecular mechanisms of cellular force sensation, and the development of new microfluidic technologies for vascularized engineered tissues and models of metastatic cancer. He is co-founder of two companies, CardioVascular Technologies, and AIM Biotech.

Before starting AIM Biotech as its cofounding CEO, Kuan Chee Mun was previously responsible for Advanced Technology Development at Becton Dickinson & Co. (Asia-Pacific), a Fortune 500 medical device multinational company. He focused on identifying new business opportunities and developing product concepts & technologies to address unmet needs of customers from China, India and other Asia Pacific economies. Prior to this appointment, Chee Mun was the General Manager for the first international subsidiary of the Johns Hopkins University School of Medicine, based in Singapore. He began his career in academic research in molecular biology, and later joined the Singapore National Science & Technology Board. Chee Mun holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science (Honours) in Cell & Molecular Biology from the National University of Singapore.